<DOC>
	<DOCNO>NCT01106352</DOCNO>
	<brief_summary>The main purpose study establish recommend dose Alpharadin use combination docetaxel patient bone metastases castration-resistant prostate cancer investigate safety explore efficacy recommend dose .</brief_summary>
	<brief_title>A Study Alpharadin With Docetaxel Patients With Bone Metastasis From Castration-Resistant Prostate Cancer ( CRPC )</brief_title>
	<detailed_description>The trial initially conduct submit Algeta ASA . After acquire Algeta , Bayer sponsor .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate . Two bone metastasis ( hot spot ) confirm bone scintigraphy within 8 week prior study entry Known castrationresistant disease Karnofsky Performance Status ( KPS ) : ≥70 % within 14 day start study treatment ( ECOG 1 ) Life expectancy least 6 month . Acceptable hematology serum biochemistry screen value Eligible use docetaxel accord product information ( package insert similar ) . Has receive investigational therapeutic drug within last 4 week prior start study treatment , schedule receive one treatment period . Has receive external radiotherapy within last 4 week prior start study treatment . Has immediate need radiotherapy . Has receive prior hemibody external radiotherapy . Has receive systemic radiotherapy ( e.g . samarium , strontium etc . ) treatment bone metastasis . Has receive cytotoxic chemotherapy within last 4 week prior start study treatment , recover grade 1 0 adverse event due cytotoxic chemotherapy administer 4 week earlier . Has receive ten previous infusion docetaxel . Previous known experience grade ≥ 3 docetaxel related toxicity docetaxel toxicity relate dose interruption discontinuation . Previous use GCSF persistent neutropenia docetaxel treatment . Has receive blood transfusion erythropoietin ( EPO ) within last 4 week prior start study treatment . Has receive prior treatment Alpharadin . Malignant lymphadenopathy exceed 3 cm shortaxis diameter . Symptomatic nodal disease , i.e . scrotal , penile leg edema . Visceral metastasis CRPC ( &gt; 2 lung and/or liver metastases [ size ≥2cm ] ) , assess CT scan MRI chest/abdomen/pelvis within last 8 week prior start study treatment . Uncontrolled locoregional disease . Other primary tumor ( CRPC ) include haematological malignancy present within last 5 year ( except nonmelanoma skin cancer lowgrade superficial bladder cancer ) . Has imminent establish spinal cord compression base clinical finding and/or MRI . Unmanageable fecal incontinence</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>The target population patient bone metastasis castration-resistant prostate cancer intend treatment docetaxel</keyword>
</DOC>